SLC5A2 and diabetes mellitus: The RR for ketoacidosis in patients with diabetes allocated to an SGLT2 inhibitor, compared with placebo, was 2·12 (1·49–3·04; figure 4) and there was no evidence that this differed when trial results were ordered by mean baseline eGFR (appendix p 21).